Protagonist Therapeutics
PTGX81
$45.63arrow_drop_down0.93%-$0.42
PTGX81
$45.63
arrow_drop_down0.93%| Key Stats | |
|---|---|
| Open | $45.69 |
| Prev. Close | $45.91 |
| EPS | 4.23 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 44.58 | 45.95 |
| 52 Week Range | 13.72 | 60.57 |
| Ratios | |
|---|---|
| EPS | 4.23 |
| Fundamentals | |
|---|---|
| Payout Ratio | - |
| Industry average yield | 2.89% |
| Last Dividend pay date | - |
| Dividend per share | - |
| Dividend yield forecast | - |
Stock Analysis
Technicals
Summarizing what the indicators are suggesting.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Analyst rating
An aggregate view of professional's ratings.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Stock Performance
PTGX-
US Healthcare Sector-
US Market-
warning
PTGX / Market
PTGX lose to the US Market which returned 0.03% over the last twenty four hours.warning
PTGX / Healthcare Sector
PTGX lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.Protagonist Therapeutics (PTGX) Statistics
Keep an eye on Protagonist Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
How has Protagonist Therapeutics (PTGX) stock's performance compared to its sector and the market over the past year?
Over the past year, Protagonist Therapeutics (PTGX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Protagonist Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Protagonist Therapeutics 's performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of Protagonist Therapeutics (PTGX) stock?
The PE (Price to Earnings) ratio of Protagonist Therapeutics (PTGX) is currently 10.79. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help
What is the EPS of Protagonist Therapeutics (PTGX) stock?
The Earnings Per Share (EPS) for Protagonist Therapeutics (PTGX), calculated on a diluted basis, is $4.23. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of Protagonist Therapeutics (PTGX) stock?
The operating margin for Protagonist Therapeutics (PTGX) is 74.3%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of Protagonist Therapeutics (PTGX) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Protagonist Therapeutics (PTGX) is $255.74M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does Protagonist Therapeutics (PTGX) have?
Protagonist Therapeutics (PTGX) has a total debt of $10.87M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$86.38M.